Rare and Orphan Disease Trials

FDA Expectations for Natural History Evidence in Rare Disease Trials

Posted on digi By digi

Natural history studies have become a regulatory cornerstone in the development of therapies for rare diseases. The U.S. Food and Drug Administration (FDA) recognizes the challenges of limited patient populations, disease heterogeneity, and ethical concerns that make traditional randomized controlled trials difficult in this space. As a result, natural history evidence can support trial design, endpoint justification, external controls, and even serve as baseline comparators in single-arm studies.
Click to read the full article.

Natural History Studies, Rare and Orphan Disease Trials

Adaptive Trial Success in Ultra-Rare Genetic Syndromes

Posted on digi By digi

Ultra-rare genetic syndromes, often defined as conditions affecting fewer than one in 50,000 individuals, present unique barriers to traditional clinical development. With small patient populations scattered globally, conventional randomized controlled trials (RCTs) are often infeasible. Adaptive trial designs—where trial parameters such as sample size, dosing, or randomization ratios can be modified mid-study without undermining statistical integrity—have emerged as powerful solutions. They provide the flexibility to extract meaningful insights from limited patient numbers, reduce trial costs, and expedite regulatory decision-making.
Click to read the full article.

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

Using Real-World Data to Inform Disease Progression in Rare Conditions

Posted on digi By digi

Understanding disease progression is one of the foundational steps in rare disease clinical research. However, the scarcity of patients, heterogeneity in symptoms, and limited trial opportunities make it difficult to capture long-term, meaningful data. In this context, real-world data (RWD) provides an invaluable source of observational insights that complement traditional clinical trial datasets.
Click to read the full article.

Natural History Studies, Rare and Orphan Disease Trials

Data Monitoring Committees in Small Population Studies: Roles and Challenges

Posted on digi By digi

Data Monitoring Committees (DMCs), also known as Data and Safety Monitoring Boards (DSMBs), are independent groups tasked with safeguarding patient safety and maintaining trial integrity. In rare disease clinical trials—often involving small, vulnerable populations and novel therapies—the role of the DMC becomes even more critical.
Click to read the full article.

Operational Challenges, Rare and Orphan Disease Trials

Breakthroughs in Cell Therapy for Rare Blood Disorders

Posted on digi By digi

Rare blood disorders such as severe aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH), and beta-thalassemia have long lacked effective treatments. Traditional therapies—blood transfusions, immunosuppressants, or bone marrow transplants—often provided only partial or temporary relief. The advent of advanced cell therapy approaches, particularly CAR-T cells, gene-edited stem cells, and autologous transplants, has reshaped the therapeutic landscape. These innovations hold the potential for long-term remission and even cures.
Click to read the full article.

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

Case Study: SMA Type I Natural History Study and Its Regulatory Impact

Posted on digi By digi

Spinal Muscular Atrophy (SMA) Type I is one of the most severe and rapidly progressing rare diseases affecting infants. With onset typically before six months of age, SMA Type I results in progressive motor neuron loss, profound muscular weakness, and often leads to death or permanent ventilation by two years of age. In the absence of treatment, most affected infants never sit unassisted and face devastating outcomes.
Click to read the full article.

Natural History Studies, Rare and Orphan Disease Trials

Culturally Sensitive Communication in Global Rare Disease Trials

Posted on digi By digi

As rare disease clinical trials increasingly expand across borders, the need for culturally sensitive communication becomes more critical. Many rare diseases are so infrequent that patient populations are geographically dispersed, requiring sponsors to open study sites across multiple countries and cultural contexts. In such environments, success hinges on more than protocol design—it depends on trust, understanding, and respectful engagement with diverse communities.
Click to read the full article.

Ethics & Patient Engagement, Rare and Orphan Disease Trials

Global Collaboration Leading to Rare Disease Drug Approval

Posted on digi By digi

Rare disease research faces unique challenges—tiny patient populations, fragmented data sources, and a scarcity of clinical trial sites. No single country can overcome these obstacles alone. This reality has driven unprecedented levels of international collaboration among regulators, academic researchers, biopharma sponsors, and patient organizations. A landmark example of this collective effort was the global approval of therapies for ultra-rare disorders, achieved through cross-border trial participation, harmonized regulatory standards, and joint data analysis.
Click to read the full article.

Case Studies & Breakthroughs, Rare and Orphan Disease Trials